

SUBSTANTIAL SHAREHOLDERS

SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the [REDACTED] (assuming that the [REDACTED] is not exercised and without taking into account any Shares which may be allotted and issued under the Equity Incentive Plan), the following persons will have interests or short positions in the Shares or underlying Shares of our Company which would fall to be disclosed to our Company pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or will be, directly or indirectly, interested in 10% or more of the issued voting shares of any other member of our Group.

Shareholder	Nature of interest	Number of Shares interested in as of the Latest Practicable Date ⁽¹⁾⁽²⁾	Approximate percentage of interest in our Company as of the Latest Practicable Date ⁽²⁾ (%)	Number of Shares interested in immediately following the completion of the [REDACTED] ⁽¹⁾⁽²⁾	Approximate percentage of interest in our Company immediately following the completion of the [REDACTED] ⁽²⁾ (%)
Dr. Tian	Beneficial interest	55,233,000 (L)	30.44	[REDACTED] (L)	[REDACTED]
Dr. Ivanov	Beneficial interest	27,616,000 (L)	15.22	[REDACTED] (L)	[REDACTED]
AZ-CICC ⁽⁴⁾	Beneficial interest	10,730,688 (L)	5.91	[REDACTED] (L)	[REDACTED]
AZ Investment Consulting ⁽⁴⁾	Interest in controlled corporation	10,730,688 (L)	5.91	[REDACTED] (L)	[REDACTED]
AZ China ⁽⁴⁾	Interest in controlled corporation	10,730,688 (L)	5.91	[REDACTED] (L)	[REDACTED]
AstraZeneca ⁽⁴⁾	Interest in controlled corporation	10,730,688 (L)	5.91	[REDACTED] (L)	[REDACTED]
CICC Capital Management ⁽⁴⁾	Interest in controlled corporation	10,730,688 (L)	5.91	[REDACTED] (L)	[REDACTED]
CICC ⁽⁴⁾	Interest in controlled corporation	10,730,688 (L)	5.91	[REDACTED] (L)	[REDACTED]
YF Digital Health ⁽⁵⁾	Beneficial interest	10,730,688 (L)	5.91	[REDACTED] (L)	[REDACTED]
YF Fund IV ⁽⁵⁾	Interest in controlled corporation	10,730,688 (L)	5.91	[REDACTED] (L)	[REDACTED]
YF Fund IV GP ⁽⁵⁾	Interest in controlled corporation	10,730,688 (L)	5.91	[REDACTED] (L)	[REDACTED]
Mr. Yu	Interest in controlled corporation	10,730,688 (L)	5.91	[REDACTED] (L)	[REDACTED]

Notes:

- (1) The letter "L" denotes the person's long position in the Shares.
- (2) On the basis that the Preferred Shares will be converted into the Shares on a one-to-one basis by way of re-designation and re-classification immediately before the [REDACTED].

SUBSTANTIAL SHAREHOLDERS

- (3) Based on the assumption that the [REDACTED] is not exercised and without taking into account any Shares which may be allotted and issued under the Equity Incentive Plan.
- (4) The general partners of AZ-CICC are AstraZeneca Investment Consulting (Wuxi) Co., Ltd. (阿斯利康商務諮詢(無錫)有限公司) ("**AZ Investment Consulting**") and CICC Private Equity Management Co., Ltd. (中金私募股權投資管理有限公司) ("**CICC Capital Management**"). AstraZeneca Investment Consulting is wholly owned by AZ Investment (China) Co., Ltd. (阿斯利康投資(中國)有限公司) ("**AZ China**"). AZ China is wholly owned by AstraZeneca PLC ("**AstraZeneca**"), a public limited company with the principal markets for trading on the London Stock Exchange, Nasdaq Stockholm and Nasdaq Global Select market (ticker symbol: AZN). CICC Capital Management is wholly owned by China International Capital Corporation Limited (中國國際金融股份有限公司) ("**CICC**"), a company listed on the Stock Exchange (stock code: 03908) and the Shanghai Stock Exchange (stock code: 601995). As such, each of AZ Investment Consulting, AZ China, AstraZeneca, CICC Capital Management and CICC is deemed to be interested in the Shares held by AZ-CICC under the SFO.
- (5) YF Digital Health Limited ("**YF Digital Health**") is wholly owned by Yunfeng Fund IV AIV II, L.P. ("**YF Fund IV**"). The general partner of YF Fund IV is Yunfeng Fund IV AIV GP, Ltd. ("**YF Fund IV GP**"). None of the limited partners of YF Fund IV holds more than one-third of the partnership interest. YF Fund IV GP is controlled by Mr. Feng Yu (虞鋒) ("**Mr. Yu**"). As such, each of YF Fund IV, YF Fund IV GP and Mr. Yu is deemed to be interested in the Shares held by YF Digital Health under the SFO.

Save as disclosed above, our Directors are not aware of any person who will, immediately following the completion of the [REDACTED] (assuming that the [REDACTED] is not exercised and without taking into account any Shares which may be allotted and issued under the Equity Incentive Plan), have any interest and/or short position in the Shares or underlying Shares of our Company which will fall to be disclosed to our Company pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or who will be, directly or indirectly, interested in 10% or more of the issued voting shares of any other member of our Group.